---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-267697"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:07:25.549261+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aldeyra grants AbbVie exclusive option to co-develop reproxalap; $1M upfront, $100M upon exercise

## Summary
- AbbVie pays $1M non-refundable option fee; can extend option for $5M if FDA decision delayed past Dec 15, 2023.
- Upon exercise, AbbVie pays $100M upfront (less prior payments); Aldeyra eligible for up to ~$300M in regulatory and commercial milestones.
- In the US, profits/losses split 60% AbbVie, 40% Aldeyra; outside US, Aldeyra receives tiered royalties on net sales.
- AbbVie gets right of first negotiation on Aldeyra's other ocular surface compounds and data review rights.
- Option expires Dec 23, 2023 if not exercised or extended; tied to FDA decision on reproxalap NDA.

## SEC filing metadata
- accession: 0001193125-23-267697
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/0001193125-23-267697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/d857697d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-267697
- JSON: https://secwatch.observer/filing/0001193125-23-267697.json
- Plain text: https://secwatch.observer/filing/0001193125-23-267697.txt

## Key facts
- Material Agreements
  Aldeyra Therapeutics, Inc. entered into Option Agreement with AbbVie Inc. valued at $1 million (effective 2023-10-31).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: AbbVie Inc.
  - Value: $1 million
  - Effective: 2023-10-31
  source text: On October 31, 2023 (the “Effective Date”), Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) entered into an exclusive option agreement (the “Option Agreement”) with AbbVie Inc. (“AbbVie”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312523267697/0001193125-23-267697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.